Biotinylated Human FGFR4 Protein
Beta LifeScience
SKU/CAT #: BLK-02158P-100UG
Biotinylated Human FGFR4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human FGFR4 Protein
Beta LifeScience
SKU/CAT #: BLK-02158P-100UG
Collections: Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human FGFR4 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Leu22-Asp369. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P22455 |
Target Symbol | FGFR4 |
Synonyms | CD334; FGF R4; FGFR4; FGFR-4; MGC20292; JTK2; TKF |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Leu22-Asp369 |
Mol. Weight | The protein has a predicted MW of 41.4 kDa. Due to glycosylation, the protein migrates to 55-72 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Fibroblast growth factor receptor 4 (FGF R4), also known as CD334, is a 110 kDa glycosylated transmembrane receptor tyrosine kinase.Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. |